Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

Roche Basel Switzerland

Roche’s melanoma combo “too expensive” for NHS use, says NICE

Cost-effectiveness body rejects Cotellic/Zelboraf despite acknowledging survival benefits

- PMLiVE

Portrait exhibition raises refugee healthcare profile

Doctors of the World opens gallery to mark 10-year anniversary of its London clinic

AstraZeneca AZ

AstraZeneca to explore link between epigenetics and respiratory diseases

Joins forces with Asthma UK, the British Lung Foundation and MRC Technology

- PMLiVE

Allergan CEO takes issue with ‘predatory’ price increases

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

- PMLiVE

Daiichi Sankyo promotes Dr Marielle Cohard-Radice

She becomes executive vice president, global head of development

- PMLiVE

Bexsero halved UK meningitis B cases in first year, says study

GSK hopes success of its UK vaccination campaign will encourage replication worldwide

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

- PMLiVE

Proteostasis Therapeutics strengthens leadership team

James DeTore, Geoffrey Gilmartin and Marija Zecevic join

- PMLiVE

Repositive appoints scientific lead

Manuel Corpas joins the genome software company

- PMLiVE

Nestlé Health Science buys medical device firm

Acquisition of UK's Phagenesis expected to be completed by 2019

- PMLiVE

Clinton takes aim at pharma pricing once again

Pledges to establish new enforcement powers to address “unjustified price hikes”

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links